Biggest News Aggregation in the World
📰 Notable Labs News

Page 2 - Notable Labs News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Notable Labs. Real-time updates on events, politics, business and more.

Notable Labs, Ltd. (NASDAQ:NTBL) Forecasted to Earn FY2024 Earnings of ($1.21) Per Share

Notable Labs, Ltd. (NASDAQ:NTBL – Free Report) – Analysts at Chardan Capital issued their FY2024 earnings estimates for shares of Notable Labs in a research report issued on Monday, November 20th. Chardan Capital analyst K. Nakae expects that the company will earn ($1.21) per share for the year. Chardan Capital has a “Buy” rating on […]
Labs Ltd Notable Labs Free Report Chardan Capital Get Free Report Predictive Precision Medicines Platform
Source: wkrb13.com

Daily Game Plan

TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 8:30ET Building Permits, Housing Starts; 12:00ET Fed’s Waller speaks; 12:30ET Fed’s Williams speaks; 1:00ET Fed’s Bowman and Barkin speak; 2:00ET Fed’s Beige Book; 3:15ET Fed’s Harker speaks TODAY’S HIGHLIGHTS: Biden’s summit with Arab leaders was cancelledBiden says hospital blast in Gaza 'appears
Saudi Arabia Republic Of Tel Aviv United Kingdom New Market Israel General

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT -Today at 02:49 pm

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed merger of Vascular Biogenics Ltd. operating as VBL...
United States Lewiss Kahn Charlesc Foti Jr Vascular Biogenics Ltd Kahn Swick Foti Company Nasdaq

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash equivalents as of June 30, 2023 MODI’IN, Israel and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update. “We continue to make goo...
Israel General Dror Harats Labs Inc Vascular Biogenics Ltd European Innovation Commission Group Ltd
Source: yahoo.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science